LISA VR Press Talk: current partnerships between biotech and pharma in Vienna.
Apeiron Biologics AG (Apeiron) today announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the treatment of the Acute Respiratory Distress Syndrome (ARDS).
On Nov. 17th, one of our major shareholders, business angel and Chairman of the Supervisory Board, DDr. Manfred Reichl has received the award “Business Angel of the Year“. Congratulations!